| http://www.w3.org/ns/prov#value | - Jimenez told Fortune that the Swiss drug maker ??? which markets generics and biosimilars through its Sandoz division ??? was investing heavily in biosimilars and difficult-to-make generics for such conditions as cancer and respiratory disorders.
|
